期刊文献+

紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的临床研究 被引量:1

原文传递
导出
摘要 目的:观察紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的近期疗效和毒副反应。方法:有可测量病灶,无法手术切除或术后复发、远处转移的40例Ⅲ~V晚期非小细胞肺癌患者,应用紫杉醇脂质体135mg/m^2第1天,顺铂25mg/m^2第1~3天。21天为1个周期,每化疗2个周期评价疗效。结果:总有效率为40%。其中初治者有效率为45.5%,复治者有效率为33.3%,两者比较有统计学差异(P<0.05)。病理类型中腺癌有效率为41.7%,鳞癌有效率为40%,两者比较无统计学差异(P>0.05)。毒副反应以骨髓抑制、胃肠道反应和周围神经毒性为主,且多为Ⅰ~Ⅱ级,患者耐受良好。
出处 《中国伤残医学》 2013年第6期261-262,共2页 Chinese Journal of Trauma and Disability Medicine
  • 相关文献

参考文献4

  • 1张力.晚期非小细胞肺癌的二线治疗进展[J].中国肺癌杂志,2008,11(1):4-9. 被引量:25
  • 2周际昌.最新肿瘤化疗技术操作规范与并发症防治及新型药物选用手册[M].北京:中国医科大学出版社.2006.1008. 被引量:4
  • 3Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations int [J]. J Pharm, 2002, 235(122): 1791. 被引量:1
  • 4Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy [J]. Clin Cancer Res, 2003,9(6): 2335-2341. 被引量:1

二级参考文献24

  • 1S.Niho,Y.Ichinose.T.Tamura,et al.Results of a randomized phase Ⅲ study to comparethe overall survival of gefitinib(IRESSA)versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens.ASCO Meeting 被引量:1
  • 2Douillard Jean-Yves,Kim Edward,Hirsh Vera,et al.Gefitinib(IBESSA)vergns docetsxel in patients with locally advanced or metastatic non-small-cell lung can cer pre-treated with platinum-based chemotherapy:a randomized.open-label Phase Ⅲ study(INTEREST).WCLC 2007:PRS-02. 被引量:1
  • 3Shepherd FA,Rodrignos Pereira J,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med.2005 Jul 14;353(2):123-32.Abstracts,Jun 2007;25:18018. 被引量:1
  • 4Wu,Y.Zhang,L.Au,J.Sin-Kie et al.Safety of erlotinibin TRUST,a phase Ⅳ trial in patients with advanced non-small cell lung cancer(NSCLC):Initial results from the East/South East(E/SE)Asian subgroup.ASCO Meeting 被引量:1
  • 5Ramlau R,Gervais R,Krzakowgki M,et al.Phase Ⅲ study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.J Clin Oncol.2006 Jun 20;24(18):2800-3807.Abstracts,Jun 2007;25:7511. 被引量:1
  • 6Krzakowski M,Donillard J,Ramlau R,et al.Phase Ⅲ study of vinflunine versns docetaxel in patients(pts)with advanced non-small cell lung cancer(NSCLC)previously treated with a platinum-containing regimen.ASCO Meeting 被引量:1
  • 7Bennouna J,Breton JL,Tourani JM,et al.Vinflunine-an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen:results of a phase Ⅱ study.Br J Cancer.2006,22;94(10):1383-8. 被引量:1
  • 8Chemotherapy in non small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials.BMJ,1995,311:899-909. 被引量:1
  • 9Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non small cell lung cancer.N Engl J Med,2002,346(2):92-98. 被引量:1
  • 10Bissery M C,Guenard D,Gueritte-Voegelein F,et al.Experimental antitumor activitiy of taxotere(RP56976,NSC62850 3),a taxol analogue.Cancer Res,1991,51(18),4845-4852. 被引量:1

共引文献26

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部